Frederic Bouder
Title
Cited by
Cited by
Year
The Earthscan reader in risk and modern society
R Löfstedt, L Frewer
Earthscan, 1998
1481998
The changing nature of communication and regulation of risk in Europe
R Lofstedt, F Bouder, J Wardman, S Chakraborty
Journal of Risk Research 14 (4), 409-429, 2011
972011
The tolerability of risk: a new framework for risk management
F Bouder, D Slavin, R Löfstedt
Earthscan, 2007
842007
Transparency in Europe: a quantitative study
F Bouder, D Way, R Löfstedt, D Evensen
Risk Analysis 35 (7), 1210-1229, 2015
472015
The COVID-19 pandemic: how can risk science help?
T Aven, F Bouder
Journal of Risk Research 23 (7-8), 849-854, 2020
442020
Regulating impurities in pharmaceutical products: a tolerability of risk approach?
F Bouder
Expert review of clinical pharmacology 1 (2), 241-250, 2008
292008
New transparency policies: risk communication’s doom?
RE Löfstedt, F Bouder
Effective risk communication, 99-116, 2013
282013
Evidence-based uncertainty analysis: What should we now do in Europe? A view point
R Lofstedt, F Bouder
Journal of Risk Research, 1-20, 2017
232017
Medicines transparency at the European Medicines Agency (EMA) in the new information age: the perspectives of patients
D Way, F Bouder, R Löfstedt, D Evensen
Journal of Risk Research 19 (9), 1185-1215, 2016
202016
Varieties of risk regulation in Europe: coordination, complementarity and occupational safety in capitalist welfare states
H Rothstein, D Demeritt, R Paul, AL Beaussier, M Wesseling, M Howard, ...
Socio-Economic Review 17 (4), 993-1020, 2019
182019
Pharmaceutical benefit–risk communication tools: a review of the literature
D Way, H Blazsin, R Löfstedt, F Bouder
Drug safety 40 (1), 15-36, 2017
182017
When ‘must’means ‘maybe’: varieties of risk regulation and the problem of trade-offs in Europe
H Rothstein, AL Beaussier, O Borraz, F Bouder, D Demeritt, M de Haan, ...
HowSAFE WP 1, 15, 2015
132015
Transparency and the Food and Drug Administration—A quantitative study
R Lofstedt, F Bouder, S Chakraborty
Journal of health communication 18 (4), 391-396, 2013
132013
The future of risk communication and the role of the pharmaceutical industry
S Chakraborty, F Bouder
Current drug safety 8 (1), 4-10, 2013
122013
A comparative analysis of risk perception related to human health issues
FE Bouder
Risk society and the culture of precaution, 167-183, 2006
122006
Governance for sustainable development in Canada
F Bouder
Governance for Sustainable Development: Five OECD Case Studies, 2001
122001
Risk communication of vaccines: challenges in the post-trust environment
F Bouder
Current drug safety 10 (1), 9-15, 2015
102015
Risk-based governance against national obstacles? Comparative dynamics of Europeanization in Dutch, French, and German flooding policies
R Paul, F Bouder, M Wesseling
Journal of Risk Research 19 (8), 1043-1062, 2016
92016
Benefit/risk communication by the European Medicines Agency: a study of influential stakeholders' expectations and attitudes
F Bouder
European Medicines Agency (EMA), 2011
92011
Can decoupling work?
F Bouder
Think-piece contributed to the SDC Workshop ‘Economy Lite–can decoupling work, 2008
92008
The system can't perform the operation now. Try again later.
Articles 1–20